Research & development decreased 41.0%
Research & development changed -41.0% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$988,000→$583,0004 prior comparisons
GROSSPATTERN / DETERMINISTIC EVIDENCE / V3
Search securities →CHRN financial changes
Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Gross profit decreased 40.5%
Gross profit changed -40.5% from the comparable as-filed period. The change ranks at the 100th percentile of 4 prior comparable changes.
$1.8M→$1.1M4 prior comparisons
Capital expenditure decreased 100.0%
Capital expenditure changed -100.0% from the comparable as-filed period. The change ranks at the 75th percentile of 4 prior comparable changes. This reverses 2 consecutive comparable moves in the opposite direction.
$10,000→$04 prior comparisons
Operating income decreased 63.3%
Operating income changed -63.3% from the comparable as-filed period.
-$3.4M→-$5.6M2 prior comparisons
Net income decreased 138.2%
Net income changed -138.2% from the comparable as-filed period.
-$2.9M→-$6.9M1 prior comparisons
Cash & equivalents decreased 50.4%
Cash & equivalents changed -50.4% from the comparable as-filed period.
$8.1M→$4.0M1 prior comparisons
Stock-based compensation decreased 54.4%
Stock-based compensation changed -54.4% from the comparable as-filed period.
$250,000→$114,0002 prior comparisons
Free-cash-flow proxy decreased 7.5%
Free-cash-flow proxy changed -7.5% from the comparable as-filed period. The change ranks at the 20th percentile of 5 prior comparable changes.
-$2.0M→-$2.1M5 prior comparisons
Operating cash flow decreased 8.0%
Operating cash flow changed -8.0% from the comparable as-filed period. The change ranks at the 20th percentile of 5 prior comparable changes.
-$2.0M→-$2.1M5 prior comparisons
Inventory decreased 6.3%
Inventory changed -6.3% from the comparable as-filed period.
$5.0M→$4.6M3 prior comparisons
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.